Savara Completes Public Offering with Full Exercise of Underwriters' Option, Achieving Total Gross Proceeds of $149.5 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 31 2025
0mins
Source: Newsfilter
Savara Inc. Public Offering: Savara Inc. has completed an underwritten public offering of 28,452,381 shares of common stock at $4.20 per share, raising approximately $149.5 million in gross proceeds.
Warrants and Underwriters: The offering included pre-funded warrants for 7,142,857 shares at $4.199 each, with Jefferies, Piper Sandler, and Guggenheim Securities serving as joint book-running managers.
Regulatory Compliance: The securities were offered under an existing shelf registration statement filed with the SEC, with the final prospectus supplement filed on October 30, 2025.
Company Focus: Savara is a clinical stage biopharmaceutical company specializing in rare respiratory diseases, with its lead program, MOLBREEVI, in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SVRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SVRA
Wall Street analysts forecast SVRA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.220
Low
9.00
Averages
10.17
High
11.00
Current: 6.220
Low
9.00
Averages
10.17
High
11.00
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palvella Appoints Matt Pauls to Board of Directors
- New Board Member: Palvella Therapeutics has appointed Matt Pauls to its Board of Directors, leveraging his over 25 years of experience in the rare disease biopharmaceutical sector, which is expected to enhance the company's regulatory and commercialization efforts.
- Extensive Industry Experience: Pauls has held executive roles at companies like Savara, Soleno, and Insmed, notably leading the successful commercialization of KEVEYIS® and Macrilen® at Strongbridge Biopharma, showcasing his deep expertise in product launch strategies.
- Strategic Development Opportunity: As Palvella prepares for the potential launch of QTORIN™ rapamycin, Pauls' addition is poised to provide crucial support for the company's pipeline in rare skin diseases and vascular malformations, aiding in achieving market objectives.
- Future Outlook: Pauls expressed strong conviction in Palvella's strategy and is eager to apply his extensive experience to drive rapid growth, particularly in areas lacking FDA-approved treatment options.
See More
Savara CFO Exercises Options and Sells Shares
- Executive Stock Transaction: On June 22, 2026, Savara CFO David Lowrance exercised 580,187 options and sold 394,528 shares for approximately $2.24 million, reflecting a liquidity move aligned with market confidence.
- Tax Withholding and Holdings: In this transaction, Lowrance withheld 185,659 shares for taxes, retaining 536,032 shares post-transaction, indicating ongoing confidence in the company's future.
- Market Performance and Timing: At the time of the transaction, Savara's stock was priced at $5.68 per share, with a 166.97% increase over the past year, showcasing the company's strong performance in a favorable market environment.
- Future Development Outlook: Savara is advancing its biologics license application for MOLBREEVI, which is expected to become the first approved treatment for autoimmune pulmonary alveolar proteinosis, potentially generating significant revenue for the company.
See More
Savara CFO Sells Shares Amid Health Transition
- Executive Stock Sale: On June 22, 2026, Savara's CFO David Lowrance sold 394,528 shares of common stock for approximately $2.24 million at a weighted average price of $5.68 per share, representing 42.40% of his total holdings, indicating a liquidity need due to health issues.
- Options Exercise Context: The sale was driven by the exercise of 580,187 options, with 185,659 shares withheld for tax obligations, suggesting that the transaction was primarily compensation-driven rather than a shift in confidence towards the company, reflecting financial planning by the executive.
- Company Financial Position: Savara ended the first quarter with about $203 million in cash and short-term investments, plus access to an additional $150 million in non-dilutive capital upon FDA approval, indicating strong financial positioning ahead of potential product launches.
- Regulatory Progress and Market Outlook: Savara has submitted its biologics license application to the FDA with a target action date of November 22, and if approved, it could become the first treatment for autoimmune pulmonary alveolar proteinosis, highlighting significant future market potential.
See More
Savara Inc. Grants Inducement Awards to New Employees
- Inducement Awards Granted: On June 11, 2026, Savara Inc. awarded inducement awards to four new employees, comprising options for 36,500 shares, 42,500 restricted stock units (RSUs), and 8,000 performance stock units (PSUs), aimed at attracting talent and enhancing employee loyalty.
- Stock Option Details: The granted stock options have an exercise price of $5.27 per share, aligning with the closing price on the grant date, with a 10-year term and vesting quarterly, ensuring employees remain engaged with the company.
- RSUs and PSUs Vesting: The RSUs will fully vest on the two-year anniversary of the employee's start date, while the PSUs will vest upon the company reporting quarterly revenue exceeding a specified target, further incentivizing employees to focus on company performance.
- Company Background: Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, with its lead product MOLBREEVI in Phase 3 development, addressing unmet needs in autoimmune pulmonary alveolar proteinosis, showcasing significant market potential.
See More
Savara CFO Steps Down for Health Reasons
- Executive Change: Savara's Chief Financial Officer Dave Lowrance will resign effective July 15 due to health issues, which may impact the company's financial decision-making and strategic direction.
- Role Transition: Chief Operating Officer Robert Lutz will take on the additional role of CFO, indicating a significant functional restructuring at the executive level that could affect operational efficiency and financial transparency.
- Management Redistribution: Administrative duties will be distributed among senior leadership team members, a strategy aimed at ensuring management stability during the executive transition, though it may lead to decision-making delays in the short term.
- Market Reaction: Savara's stock price may experience negative impacts due to the executive changes, particularly against the backdrop of an FDA review extension and increasing market scrutiny on its rare disease assets.
See More
Savara Presents Long-Term Efficacy Data for Molgramostim at ATS Conference
- Clinical Trial Results: Savara presented long-term efficacy data from the IMPALA-2 clinical trial at the 2026 ATS International Conference, involving 164 patients, demonstrating significant effects of Molgramostim in treating autoimmune pulmonary alveolar proteinosis (aPAP), reinforcing its potential as a treatment option.
- High Patient Retention: Following the double-blind period, 98% of patients opted to continue into the open-label (OL) phase, indicating the good tolerability of Molgramostim and strong patient endorsement of the treatment, which enhances the company's market confidence in this area.
- Sustained Efficacy Improvements: During the first 48 weeks of the OL period, patients receiving Molgramostim showed continuous improvements in pulmonary gas transfer (DLco%) and health-related quality of life (SGRQ-T and SGRQ-A scores), indicating the long-term efficacy and safety of the drug.
- Significant Crossover Effects: Patients who switched from placebo to Molgramostim during the OL period exhibited notable improvements in pulmonary gas transfer and quality of life scores, highlighting the drug's broad applicability and potential market opportunities across different patient populations.
See More
Palvella Appoints Matt Pauls to Board of Directors
- New Board Member: Palvella Therapeutics has appointed Matt Pauls to its Board of Directors, leveraging his over 25 years of experience in the rare disease biopharmaceutical sector, which is expected to enhance the company's regulatory and commercialization efforts.
- Extensive Industry Experience: Pauls has held executive roles at companies like Savara, Soleno, and Insmed, notably leading the successful commercialization of KEVEYIS® and Macrilen® at Strongbridge Biopharma, showcasing his deep expertise in product launch strategies.
- Strategic Development Opportunity: As Palvella prepares for the potential launch of QTORIN™ rapamycin, Pauls' addition is poised to provide crucial support for the company's pipeline in rare skin diseases and vascular malformations, aiding in achieving market objectives.
- Future Outlook: Pauls expressed strong conviction in Palvella's strategy and is eager to apply his extensive experience to drive rapid growth, particularly in areas lacking FDA-approved treatment options.
See More
Savara CFO Exercises Options and Sells Shares
- Executive Stock Transaction: On June 22, 2026, Savara CFO David Lowrance exercised 580,187 options and sold 394,528 shares for approximately $2.24 million, reflecting a liquidity move aligned with market confidence.
- Tax Withholding and Holdings: In this transaction, Lowrance withheld 185,659 shares for taxes, retaining 536,032 shares post-transaction, indicating ongoing confidence in the company's future.
- Market Performance and Timing: At the time of the transaction, Savara's stock was priced at $5.68 per share, with a 166.97% increase over the past year, showcasing the company's strong performance in a favorable market environment.
- Future Development Outlook: Savara is advancing its biologics license application for MOLBREEVI, which is expected to become the first approved treatment for autoimmune pulmonary alveolar proteinosis, potentially generating significant revenue for the company.
See More
Savara CFO Sells Shares Amid Health Transition
- Executive Stock Sale: On June 22, 2026, Savara's CFO David Lowrance sold 394,528 shares of common stock for approximately $2.24 million at a weighted average price of $5.68 per share, representing 42.40% of his total holdings, indicating a liquidity need due to health issues.
- Options Exercise Context: The sale was driven by the exercise of 580,187 options, with 185,659 shares withheld for tax obligations, suggesting that the transaction was primarily compensation-driven rather than a shift in confidence towards the company, reflecting financial planning by the executive.
- Company Financial Position: Savara ended the first quarter with about $203 million in cash and short-term investments, plus access to an additional $150 million in non-dilutive capital upon FDA approval, indicating strong financial positioning ahead of potential product launches.
- Regulatory Progress and Market Outlook: Savara has submitted its biologics license application to the FDA with a target action date of November 22, and if approved, it could become the first treatment for autoimmune pulmonary alveolar proteinosis, highlighting significant future market potential.
See More
Savara Inc. Grants Inducement Awards to New Employees
- Inducement Awards Granted: On June 11, 2026, Savara Inc. awarded inducement awards to four new employees, comprising options for 36,500 shares, 42,500 restricted stock units (RSUs), and 8,000 performance stock units (PSUs), aimed at attracting talent and enhancing employee loyalty.
- Stock Option Details: The granted stock options have an exercise price of $5.27 per share, aligning with the closing price on the grant date, with a 10-year term and vesting quarterly, ensuring employees remain engaged with the company.
- RSUs and PSUs Vesting: The RSUs will fully vest on the two-year anniversary of the employee's start date, while the PSUs will vest upon the company reporting quarterly revenue exceeding a specified target, further incentivizing employees to focus on company performance.
- Company Background: Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, with its lead product MOLBREEVI in Phase 3 development, addressing unmet needs in autoimmune pulmonary alveolar proteinosis, showcasing significant market potential.
See More
Savara CFO Steps Down for Health Reasons
- Executive Change: Savara's Chief Financial Officer Dave Lowrance will resign effective July 15 due to health issues, which may impact the company's financial decision-making and strategic direction.
- Role Transition: Chief Operating Officer Robert Lutz will take on the additional role of CFO, indicating a significant functional restructuring at the executive level that could affect operational efficiency and financial transparency.
- Management Redistribution: Administrative duties will be distributed among senior leadership team members, a strategy aimed at ensuring management stability during the executive transition, though it may lead to decision-making delays in the short term.
- Market Reaction: Savara's stock price may experience negative impacts due to the executive changes, particularly against the backdrop of an FDA review extension and increasing market scrutiny on its rare disease assets.
See More
Savara Presents Long-Term Efficacy Data for Molgramostim at ATS Conference
- Clinical Trial Results: Savara presented long-term efficacy data from the IMPALA-2 clinical trial at the 2026 ATS International Conference, involving 164 patients, demonstrating significant effects of Molgramostim in treating autoimmune pulmonary alveolar proteinosis (aPAP), reinforcing its potential as a treatment option.
- High Patient Retention: Following the double-blind period, 98% of patients opted to continue into the open-label (OL) phase, indicating the good tolerability of Molgramostim and strong patient endorsement of the treatment, which enhances the company's market confidence in this area.
- Sustained Efficacy Improvements: During the first 48 weeks of the OL period, patients receiving Molgramostim showed continuous improvements in pulmonary gas transfer (DLco%) and health-related quality of life (SGRQ-T and SGRQ-A scores), indicating the long-term efficacy and safety of the drug.
- Significant Crossover Effects: Patients who switched from placebo to Molgramostim during the OL period exhibited notable improvements in pulmonary gas transfer and quality of life scores, highlighting the drug's broad applicability and potential market opportunities across different patient populations.
See More
